ALLMedicine™ Lung Adenocarcinoma Center

Mar 18th, 2023 - The incidence of lung cancer is increasing year by year. The study of the proliferation and metastasis of lung adenocarcinoma cells is of positive significance to improve the prognosis of patients with lung adenocarcinoma, but there is still a lac...

Mar 18th, 2023 - Lung cancer is the leading cause of cancer-related death. Cancer immune evasion is a key barrier in the treatment of lung cancer and the development of effective anticancer therapeutics. Long-chain Acyl-CoA dehydrogenase (ACADL), a key enzyme that...

Mar 18th, 2023 - KRASG12C inhibitors have revolutionized the clinical management of patients with KRASG12C-mutant lung adenocarcinoma. However, patient exposure to these inhibitors leads to the rapid onset of resistance. In this study, we have used genetically eng...

Mar 18th, 2023 - Proto-oncogene-oriented targeted therapy has limited benefits in elderly patients with multiple primary tumors. A woman with anaplastic lymphoma kinase-positive lung adenocarcinoma developed acquired resistance after 3 years of targeted therapy wi...

Mar 16th, 2023 - The prognostic impact of EGFR mutation as major targetable somatic gene variant on lung adenocarcinoma is controversial. KRAS is another major somatic variant in lung adenocarcinoma, and a therapeutic agent for KRAS G12C became available in clinic...

Feb 6th, 2018 - Purpose In response to advances in the field, the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) recently updated their recommendations ...

Mar 10th, 2023 - Lung cancer accounts for 30% of all cancers among American war Veterans and remains the leading cause of cancer related deaths. Half of all lung cancers are metastatic non-small cell lung cancer (NSCLC), with a 2-year survival rate of 10%. Immunot...

Mar 8th, 2023 - The primary objective is to confirm Time on Treatment (TOT) related to afatinib treatment as first-line therapy in patients with Epidermal Growth Factor Receptor (EGFR) mutation-positive Non-Small Cell Lung Cancer (NSCLC). The observation in the r...

Mar 6th, 2023 - This prospective phase II study is to determine the efficacy and safety of bevacizumab maintenance therapy after concurrent chemoradiotherapy in locally advanced lung adenocarcinoma. All patients received 4 cycles of weekly docetaxel (25mg/㎡) and...

Mar 3rd, 2023 - Current management of patients with locally advanced or metastatic NSCLC, with no susceptible molecular alterations (EGFR mutation, ALK translocation, ROS1 fusion), includes combinations based on platinum in the first line of treatment, while in t...

Mar 1st, 2023 - This is an open-label, multiple center, single-arm phase II study to evaluate the safety and efficacy Pembrolizumab,Bevacizumab in combination with Chemotherapy could improve PFS in Alectinib Failed ALK-rearranged Advanced Lung Adenocarcinoma with...

Nov 22nd, 2022 - Never smokers represent a subgroup of patients with advanced lung cancer whose genetic makeup necessitates the need for targeted therapies and clinical trials aimed at improving outcomes. Compared with smokers, defined as those who smoke over 100 ...

Oct 31st, 2022 - Prognosis, treatment outcomes, and molecular characteristics have become associated with sidedness in colorectal cancers (CRCs) making the distinction an essential characteristic for consideration in decison-making.1 Right-sided CRCs (derived from...

Oct 20th, 2022 - To the Editor: Immune checkpoint inhibitors such as anti–programmed cell death protein 1 (anti–PD-1) and anticytotoxic T lymphocyte–associated protein 4 therapies are a promising class of cancer therapeutics. However, they are associated with a va.

Oct 6th, 2022 - Clinicians looking for additional options for the treatment of patients with non–small cell lung cancer (NSCLC) may soon be gaining another actionable biomarker with the emergence of exciting new data concerning targeting the cell-surface glycopro...

Oct 5th, 2022 - Shortly after osimertinib was approved for patients with non–small cell lung cancer in 2020 by the Food and Drug Administration, a patient came to me with increasing shortness of breath. He had been on erlotinib (Tarceva) for about 2 years and had...